Safety and efficacy of ipilimumab to treat advanced melanoma in the setting of liver transplantation

Ipilimumab is a first-in-class immunological checkpoint blockade agent and monoclonal antibody against Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) that has demonstrated survival benefit and durable responses in patients with metastatic melanoma. To date, solid organ transplant recipients have been exc...

Descripción completa

Detalles Bibliográficos
Autores principales: Morales, Rita E, Shoushtari, Alexander N, Walsh, Michelle M, Grewal, Priya, Lipson, Evan J, Carvajal, Richard D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4469313/
https://www.ncbi.nlm.nih.gov/pubmed/26082835
http://dx.doi.org/10.1186/s40425-015-0066-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4469313/
https://www.ncbi.nlm.nih.gov/pubmed/26082835
http://dx.doi.org/10.1186/s40425-015-0066-0

Ejemplares similares